High hopes for funding low-priority drug trials

August 2017


It's no secret that big pharma invests billions in R&D each year, despite recent headlines bemoaning the cuts companies have made to their research budgets in recent years. This investment in exploratory-stage compounds has resulted in a robust pipeline of promising new therapies across a number of disease areas, which could save and improve millions of lives the world over. However, how many of these potential new drugs are being shelved indefinitely because of a lack of resources to fund costly and time-intensive clinical trials? In this article, Ben van der Schaaf at Arthur D. Little, discusses that although not every pipeline drug can get blockbuster funding, there are ways to breathe new life into neglected products.